A detailed history of Financial Symmetry Inc transactions in Provectus Biopharmaceuticals, Inc. stock. As of the latest transaction made, Financial Symmetry Inc holds 10,191 shares of PVCT stock, worth $1,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,191
Previous 10,191 -0.0%
Holding current value
$1,324
Previous $1.29 Million 22.33%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

BUY
$0.06 - $0.16 $611 - $1,630
10,191 New
10,191 $978,000

Others Institutions Holding PVCT

About PROVECTUS BIOPHARMACEUTICALS, INC.


  • Ticker PVCT
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 419,496,992
  • Market Cap $54.5M
  • Description
  • Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal ...
More about PVCT
Track This Portfolio

Track Financial Symmetry Inc Portfolio

Follow Financial Symmetry Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Symmetry Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Symmetry Inc with notifications on news.